- LTS Lohmann Therapie-Systeme AG has completed its acquisition of Renaissance Lakewood, LLC, a US-based CDMO specialising in nasal sprays and sterile dosage forms.
- The deal expands LTS’s global CDMO capabilities, adding around 500 employees and a new division focused on nasal and sterile drug products.
LTS Lohmann Therapie-Systeme AG has announced the successful completion of its acquisition of Renaissance Lakewood, LLC (“Renaissance”), a US-based contract development and manufacturing organisation (CDMO) specialising in nasal sprays and sterile dosage forms. The transaction, initially announced on 13 October 2025, has now closed following regulatory approvals. The financial terms of the agreement were not disclosed.
Through this acquisition, Renaissance’s facilities and team of approximately 500 employees join the LTS network, which already operates sites in Germany, the United States, and Israel. The move broadens LTS’s capabilities within the CDMO sector, strengthening its global position in innovative drug delivery and contract manufacturing.
Renaissance will now operate as a new division under the name LTS Nasal & Sterile Drug Products. The division will be led by Serge Maltais, formerly President and Chief Executive Officer of Renaissance, who will assume the role of President and General Manager within LTS.
“With the closing of this transaction, we are proud to welcome Renaissance Lakewood to the LTS family. By combining strengths, we can create more impact – for our partners, our patients, and the broader healthcare community.”
Bas van Buijtenen, CEO of LTS
According to LTS, the integration of Renaissance will enhance its capacity to deliver advanced dosage forms and expand its CDMO service offering for global pharmaceutical partners.
